MJMostafa Jihad

Mostafa Jihad

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mostafa Jihad has a total of 6 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Indications, Causes, and Patient Risk Factors for Revision After Total Ankle Arthroplasty: A Descriptive Cross-Registry Analysis of the NJR, AOANJRR, and SwedAnkle Registries

    by Sedeek Mosaid, Yousif Jihad, Mostafa Jihad, Ashok Marudanayagam, Paul Lee

    Background/Objectives: Total ankle arthroplasty (TAA) is increasingly used to treat end-stage ankle arthritis, but comprehensive cross-registry data on revision patterns remain limited. This study describes indications, causes, and patient risk factors for revisions using three national registries. Methods: Aggregate data were extracted from the UK National Joint Registry (NJR; 22nd Annual Report 2025; n = 11,321), the Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR; 2025 Ankle Supplementary Report; n = 5379), and the Swedish Ankle Registry (SwedAnkle; Annual Report 2024; n = 1852; survival estimates from a published sub-cohort, n = 1226). Metrics were compared descriptively without inferential pooling. Results: Across registries, 18,552 primary TAAs were identified. Ten-year cumulative per cent revision (CPR) was 9.54% (95% confidence interval [CI], 8.75–10.39) in the NJR, 13.5% (95% CI, 12.1–15.1) in the AOANJRR osteoarthritis sub-cohort, and approximately 26% (author-derived from Kaplan–Meier curves; see Methods) in SwedAnkle (1993 onwards implants). Aseptic loosening was the predominant cause of revision in all three registries; the rank of subsequent causes differed between registries (infection was second in the NJR and AOANJRR; in SwedAnkle, infection ranked below insert wear/breakage at 11.5%). AOANJRR Cox analysis identified younger age (hazard ratios (HRs), 2.00 for p = 0.001), earlier surgical era (HR, 1.91 for pre-2015 vs. 2015–2024; 95% CI, 1.53–2.38; p < 0.001), and obesity (HR, 1.52 for body mass index (BMI) ≥ 30; 95% CI, 1.06–2.19; p = 0.023) as significant independent predictors in AOANJRR Cox proportional hazards models (osteoarthritis sub-cohort for age, sex, BMI and ASA; all-diagnoses primary cohort for surgical era). Sex and American Society of Anesthesiologists (ASA) scores were not significant. Conclusions: Aseptic loosening was the predominant cause of revision in all three registries. The rank of subsequent causes differed: in the NJR and AOANJRR, infection was the second most frequent cause; in SwedAnkle, infection ranked below insert wear/breakage. Younger age, obesity, and earlier surgical era were independent predictors of revision in AOANJRR Cox proportional hazards models. The post-2015 era was associated with approximately 48% lower revision hazard; this association cannot be interpreted causally, as the independent contributions of implant design, surgical technique, patient selection, and other secular changes cannot be isolated from registry data. These findings may inform preoperative counselling, implant selection, and registry harmonisation efforts.

  • Open Access

    Tissue Engineering for Massive Bone Defects: The Volumetric Scaling Problem and Strategies to Solve It

    by Sedeek Mosaid, Yousif Jihad, Mostafa Jihad, Ashok Marudanayagam, Paul Lee

    Massive segmental bone defects present significant challenges in orthopaedic and maxillofacial reconstruction. As defect size increases, the disparity between tissue volume and diffusion-limited biological processes becomes more pronounced. This narrative review analyses distinctions between centimetre-scale defects and conventional fractures and evaluates current tissue-engineering strategies in relation to vascularisation, osteogenesis, mechanical stability, immune response, neural integration, and manufacturability. This review synthesises evidence from scaffold design, cell-based approaches, growth factor delivery, type-H vessel biology, NGF–TrkA signalling, large-animal models, and early clinical translation. Current findings indicate that no single scaffold, cell source, or growth factor can reliably reproduce the coordinated biological and mechanical environment required for durable regeneration of human long bones. The strongest preclinical evidence is derived from ovine tibial models employing medical-grade polycaprolactone/β-tricalcium phosphate composites or mechanobiologically optimised titanium lattices. Human data remain limited to case reports and small early clinical series, including hybrid vascularised flap–scaffold reconstructions. Successful clinical translation will require patient-specific constructs that integrate rapid vascularisation, appropriate load sharing, immune-compatible degradation, infection control, and scalable manufacturing. Until robust comparative clinical evidence emerges, established reconstructive methods will remain the standard of care. Hybrid vascularised scaffold-guided strategies should be regarded as promising translational approaches rather than definitive solutions.

  • Open Access

    Articular Cartilage Tissue Engineering: Cells, Bioinstructive Scaffolds, Immunological Microenvironment, and Emerging Technologies

    by Sedeek Mosaid, Yousif Jihad, Mostafa Jihad, Ashok Marudanayagam, Paul Lee

    Focal articular cartilage defects retain limited intrinsic repair capacity owing to the avascular, alymphatic and aneural nature of hyaline cartilage. Marrow-stimulation procedures often generate mechanically inferior fibrocartilage with declining benefit within 2–5 years in larger or high-demand lesions, while matrix-induced autologous chondrocyte implantation (MACI) achieves durable 10-year benefit but remains constrained by two-stage logistics, in vitro dedifferentiation and cost. This review integrates the cellular, biomaterial, biochemical and immunological dimensions of articular cartilage tissue engineering with quantitative benchmarks and a critical reading of failure modes, scalability and regulatory standing. We benchmark MACI against single-stage chondron- and progenitor-based therapies; examine mesenchymal stromal cells (MSCs) from bone marrow, adipose, synovium and the infrapatellar fat pad with a mechanistic dissection of the Wnt/β-catenin, IHH–PTHrP, RUNX2/MEF2C and HIF-1α inputs driving hypertrophic drift; reframe scaffolds as bioinstructive environments delivering mechanical, biochemical and tribological cues, including stimuli-responsive and 4D-printed systems and low-intensity pulsed ultrasound (LIPUS) as a non-invasive adjunct; develop the immunological dialogue between altered native cartilage, the infrapatellar fat pad–synovium unit and engineered constructs; and appraise CRISPR-based cell engineering and artificial-intelligence applications in biofabrication. We classify the principal approaches into four explicit translational tiers so that the evidentiary standing of each strategy is transparent. Translation will be paced by standardised potency assays, immune-aware construct design and robust long-term in vivo evidence.